Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.
Lazaridis
K N
KN
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 55905, USA.
Gores
G J
GJ
Lindor
K D
KD
D000818:Animals; D001649:Bile Duct Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D014580:Ursodeoxycholic Acid / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use
D014580:Ursodeoxycholic Acid